Latest News

Avelumab and axitinib approved for treatment of renal cell carcinoma

(HealthDay)—Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma (RCC) in combination with axitinib, the U.S. Food and Drug Administration announced.

Source link

Related posts

Global Mechanical Ventilators Market Analysis, Size, Share, Growth & Trends – Forecast 2018-2026 –


Wake Forest Baptist Health receives $1.6 million grant to test iPad colon cancer screening app


Frustration Mounts as EpiPen Shortage Hits 1 Year


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy